As Biosimilar Revenues Fall, Amgen Looks To Next Wave For Growth
US Adalimumab Launch Looms As Other Pipeline Candidates See Success In Trials
Executive Summary
With previously leading Amgen biosimilars such as Mvasi (bevacizumab) and Kanjinti (trastuzumab) seeing their sales decline, the firm is turning its attention to the next wave of biosimilars that will drive future growth.
You may also be interested in...
Stelara Settlement Gives Amgen US Ustekinumab Entry Date
A settlement reached in US patent litigation over Janssen’s Stelara will allow Amgen to launch its ABP 654 ustekinumab biosimilar no later than 1 January 2025. It remains to be seen whether other ustekinumab developers will follow suit.
Is The Bloom Off The Rose For Big Pharma And Biosimilars?
After a wave of big pharma interest in the biosimilars arena, originator enthusiasm for the sector appears to be waning – potentially opening up an opportunity for newcomers to compete on off-patent biologics.
Alvotech And Teva File US Stelara Rival Ahead Of 2023 Expiry
Alvotech and marketing partner Teva have confirmed that their AVT04 proposed ustekinumab biosimilar rival to Stelara has been filed with the US FDA, ahead of a key patent expiry later this year.